Connect Sign In
ARUP’S new test is the first of its kind to use two distinct biomarkers to identify in utero exposure to kratom, an herbal supplement that may cause neonatal abstinence syndrome.
The Fall 2022 edition of Magnify: The Art and Science of Diagnostic Medicine, shares how ARUP has applied what it learned from COVID-19 to improve operations, services, and, ultimately, patient care.
The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
Based on data from 21,916 participants in 33 studies, the Association for the Advancement of Blood and Biotherapies (AABB) has issued guidelines for use of convalescent plasma in COVID-19 treatment.
The National Institute of Allergy and Infectious Diseases has awarded Medical Director Allison Carey, MD, PhD, $1.5 million over five years to fund her groundbreaking research.
NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership.
New research published in Blood sheds light on diagnosis, disease characteristics, and prognoses for inherited hematologic malignancies associated with DDX41 germline variants.
A new study for which ARUP provided COVID-19 testing and expertise found that emergency department workers early in the pandemic faced the highest risk of infection from community spread.
ARUP’s latest autonomous intelligent vehicle (AIV) is on a mission to save time and trouble for its coworkers in the lab. As a new teammate, the AIV is a seamless and helpful fit.
The Summer 2022 edition of Magnify, now online, features a look at the challenges of autoimmune neurologic testing, our experts in this area, and recent awards, and catches up with a former fellow.
ARUP medical directors and scientists will share their research and expertise in areas like lab stewardship, biochemical genetics, and neonatal drug testing at AACC’s 2022 annual meeting in Chicago.
Scientist Michael T. Pyne shares ARUP’s challenges and process of developing a next generation sequencing (NGS) test for HIV-1 antiretroviral drug resistance.
